RESUMO
The presented data show the combined sequential use of i.v. G for 14 days followed by PO G for 90 days is a much more effective prophylaxis for CMVD after heart transplantation than use of i.v. G for 14 days followed by PO A for 90 days. A need for hospitalization due to CMVD is significantly reduced by this new strategy. The follow-up in group II is shorter than in group I but is now at least 6 months in group II, without any new cases in the first 6 months after cardiac transplantation. Some currently unknown adverse effect of prolonged PO G, which may be present, is not identified in this analysis.
Assuntos
Antivirais/uso terapêutico , Infecções por Citomegalovirus/prevenção & controle , Ganciclovir/uso terapêutico , Transplante de Coração , Administração Oral , Adolescente , Adulto , Idoso , Antivirais/administração & dosagem , Esquema de Medicação , Feminino , Ganciclovir/administração & dosagem , Humanos , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/prevenção & controle , Estudos Retrospectivos , Fatores de TempoRESUMO
Immediately following a double-toe transfer to her hand, a 40-year-old woman developed a severe migraine headache unrelieved by narcotics. Medical consultation was obtained, and available medical treatments were discussed in relation to their possible effects on the patient's recent microvascular procedure. Intravenous steroids were administered, with resolution of the headache. This case illustrates an approach to the management of medical problems in which treatment options are weighed against their possible microsurgical effects.
Assuntos
Amputação Traumática/cirurgia , Dexametasona/uso terapêutico , Traumatismos dos Dedos/cirurgia , Microcirurgia , Transtornos de Enxaqueca/tratamento farmacológico , Complicações Pós-Operatórias/tratamento farmacológico , Dedos do Pé/transplante , Adulto , Feminino , HumanosRESUMO
Six patients required fluorinated quinolone therapy for a variety of infections after heart transplantation. In contrast to findings in a previous report, none of the patients showed any evidence of nephrotoxicity or required a significant change in cyclosporine dose during the treatment period.